Abbott reported a sharp jump in Diagnostics revenue growth tied to its Exact Sciences acquisition, lifting Q2 Diagnostics sales 42% to $3.09 billion and raising full-year 2026 adjusted EPS guidance. The company attributed momentum to cancer diagnostic expansion, including contributions from the acquired cancer diagnostics segment. Abbott also reiterated catalysts tied to Cologuard ramp-ups, expected pricing tailwinds for the next-generation Cologuard Plus, and progress on Cancerguard plus minimal residual disease initiatives. Management said the transition supports international expansion with added government momentum. The competitive angle is that Abbott is positioning as a multi-modality screening provider—stool-based today, with blood-test optionality highlighted as attractive if regulatory approvals arrive.